Abatacept as add-on therapy for rheumatoid arthritis
Allison C
Record ID 32005001209
English, French
Authors' objectives:
The aim of this report is to review the available information on the use of Abatacept (also known as CTLA4Ig) as a co-stimulation blocker that inhibits T-cell activation and interrupts the process leading to inflammation in rheumatoid arthritis (RA). Bristol-Myers Squibb Co.(US) is developing abatacept (under the proposed trade name Orencia) for the treatment of moderately to severely active RA.
Authors' results and conclusions:
Patients with severe arthritis who took abatacept with at least one other disease-modifying antirheumatic drug in six and 12-month clinical trials demonstrated statistically significant improvement in tender, swollen joints and other clinical measures compared with placebo. Mild to moderate adverse events included headache, nasopharyngitis, hypertension and back pain, similar to those seen in placebo groups.
Authors' recommendations:
Abatacept should not be used in combination with other biologic agents because of reported increased rates of serious adverse events, including serious infections. With its different mechanism of action, abatacept may be an alternative add-on therapy for patients with an inadequate response to other arthritis therapies. Head-to-head comparisons with other biologic agents would help provide direct comparative risks and benefits, including abatacept's ability to modify the destructive component of the disease.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antirheumatic Agents
- Arthritis, Rheumatoid
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.